

***Evaluation of Serum Soluble Fractalkine
Level as a Marker of Disease Activity in
Systemic Lupus Erythematosus***

Thesis

*Submitted for Partial Fulfillment of Master Degree in Clinical
and Chemical Pathology*

By

Amany Abdallah Afify Ameria

M.B., B.CH, Faculty of Medicine

El-Menofia University

Supervised By

Prof / Mona Fathy Youssef

Professor of Clinical and Chemical Pathology

Faculty of Medicine - Ain Shams University

Dr / Abeer Ibrahim Abd El Mageed

Professor of Clinical and Chemical Pathology

Faculty of Medicine - Ain Shams University

Dr / Hala Abdel Al Ahmed

Assistant Professor of Clinical and Chemical Pathology

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2013



(قُلْ إِنَّ صَلَاتِي وَنُسُكِي وَمَحْيَايَ
وَمَمَاتِي لِلَّهِ رَبِّ الْعَالَمِينَ)

صدق الله العظيم

سورة الأنعام الآية (١٦٢)

Acknowledgment

*First of all, great thanks to **"Allah"** who gave me the strength to accomplish this work, intending to serve "God", science and the Islamic nation.*

*My sincere gratitude to **Prof. Dr/ Mona Fathy Youssef, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University,** for her kind assistance to follow closely this work, sincere encouragement and valuable criticism. It was a great honor for me to work under her supervision.*

*I am deeply thankful to **Prof. Dr/ Abeer Ibrahim Abd El Mageed, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University,** for her most generous support in every step in this work, valuable advice and precious comments.*

*I am deeply thankful to **Dr/ Hala Abdel Al Ahmed, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University,** for her most generous support in every step in this work, valuable advice and precious comments.*

To my highest symbol of manhood, my Father & my Mother.

To my husband and my beloved family who surrounded me with support, happiness and hope...

"Thank you all for being always by my side"

Contents

Title	Page
<i>List of Abbreviations</i>	i
<i>List of Figures</i>	vii
<i>List of Tables</i>	ix
INTRODUCTION	1
AIM OF THE WORK	3
REVIEW OF LITERATURE	
Chapter I: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	4
<i>A- History and Definition of SLE</i>	4
<i>B- Epidemiology of SLE</i>	5
<i>C- Types of Lupus</i>	6
<i>D- Etiology of SLE</i>	9
<i>E- Risk Factors of SLE</i>	28
<i>F- Pathogenesis of SLE</i>	31
<i>G- Complications of SLE</i>	34
<i>H- Complications of SLE in Pregnancy</i>	41
<i>I- Diagnosis of SLE</i>	43
<i>J- Diagnosis of SLE Complications</i>	53
<i>K- Assessment of SLE Disease Activity</i>	55
Chapter II: SOLUBLE FRACTALKINE (CX3CL1)	59
<i>A- Chemical Structure of Fractalkine</i>	59
<i>B- Classification of Chemokines</i>	60
<i>C- Sources of Fractalkine</i>	64

<i>D- Role of Fractalkine</i>	64
<i>E- Mode of Action of Fractalkine</i>	70
<i>F- Clinical Utility Of Fractalkine Assay</i>	71
<i>G- Assay of Fractalkine</i>	85
SUBJECTS AND METHODS	93
RESULTS	113
DISCUSSION	132
SUMMARY AND CONCLUSION	138
RECOMMENDATIONS	142
REFERENCES	143
ARABIC SUMMARY	-

List of Abbreviation

<i>α-2GPI</i>	α-2glycoprotien i
<i>AB</i>	Antibody
<i>ACA</i>	Anti cardiolipin antibody
<i>ACR</i>	American college of rheumatology
<i>ADP</i>	Adenosine diphosphate
<i>AHA</i>	Anti histone antibody
<i>AIDS</i>	Acquired immune deficiency syndrome
<i>ALT</i>	Alanine aminotransferase
<i>ANA</i>	Anti nuclear antibody
<i>ANCAs</i>	Anti-neutrophil cytoplasmic antibodies
<i>Anti rib-p</i>	Anti ribosomal protein p
<i>Anti Sm</i>	Anti smith
<i>APCs</i>	Antigen presenting cell
<i>Apo E</i>	Apolipoprotein e
<i>APS</i>	Antiphosphplipid syndrome
<i>ARF</i>	Acute renal failure
<i>AST</i>	Aspartate transaminase
<i>AUC</i>	Area under the curve
<i>B8</i>	Hla-b8
<i>BaF</i>	B cell activating factor
<i>BCA1</i>	B cell attracting chemokine 1
<i>BcL</i>	B cell lymphoma
<i>BLC</i>	B cell lymphocyte chemoattractant

<i>BLK</i>	B cell specific tyrosine kinase
<i>Blys</i>	B lymphocyte stimulator
<i>C</i>	Complement
<i>CBC</i>	Complete blood count
<i>CC</i>	Chemokine
<i>CD</i>	Cluster of differentiation
<i>CLL</i>	Chronic lymphoid leukemia
<i>CNS</i>	Central nervous system
<i>CR2</i>	Complement receptor 2
<i>CRP</i>	C reactive protein
<i>CSF</i>	Cerebro spinal fluid
<i>CT</i>	Computed tomography
<i>CTLA-4</i>	Cytotoxic t-lymphocyte antigen 4
<i>CTLs</i>	Cytotoxic t lymphocytes
<i>CVA</i>	Cerebrovascular accidents
<i>CX3CR1</i>	CX3C receptor
<i>DC</i>	Dendritic cell
<i>DLE</i>	Discoid lupus erythematosus
<i>DNA</i>	Deoxyribonucleic acid
<i>ds DNA</i>	Double stranded deoxy ribonucleic acid
<i>EBV</i>	Epstein-barr virus
<i>E-C4D</i>	Erythrocyte-bound c4d
<i>ECs</i>	Endothelial cells
<i>EDTA</i>	Ethylene diamine tetra acetic acid
<i>EFF</i>	Efficacy
<i>ELISA</i>	Enzyme linked immunosorbent assay

<i>ESR</i>	Erythrocyte sedimentation rate
<i>ESRD</i>	End stage renal disease
<i>FCGR2A</i>	Fc gamma receptor 2a
<i>FN</i>	False negative
<i>FOXP3</i>	Foxp3 antibody
<i>FP</i>	False positive
<i>GIT</i>	Gastrointestinal tract
<i>GP</i>	Glycoprotein
<i>HB</i>	Heamoglobin
<i>HIV</i>	Human immune deficiency virus
<i>HLA</i>	Human leukocyte antigens
<i>HMG</i>	High mobility group protein
<i>ICAM-1</i>	Intercellular adhesion molecule-1
<i>ICS</i>	Immune complexes
<i>IFN</i>	Interferon
<i>Ig</i>	Immunoglobulin
<i>IIF</i>	Indirect immunofluorescence
<i>IL</i>	Interleukin
<i>IQR</i>	Inter quarentile range
<i>IRF5,</i>	Interferone regulatory factor
<i>ITGAM</i>	Integrin, alpha M
<i>KDA</i>	Kilo dalton
<i>La(SSB)</i>	La ssb antibody
<i>LAC</i>	Lupus anticoagulant
<i>LIA</i>	Line immune-assay
<i>LN</i>	Lupus nephritis

<i>MCP</i>	Monocyte chemoattractant protein
<i>MCTD</i>	Mixed connective tissue disease
<i>MDD</i>	Minimum detectable dose
<i>MHC</i>	Major histocompatibility complex
<i>MRA</i>	Magnetic resonance angiography
<i>MRI</i>	Magnetic resonance imaging
<i>MRNA</i>	Messenger ribonucleic acid
<i>MS</i>	Multiple sclerosis
<i>ND</i>	Neutralization dose
<i>NHD</i>	Normal healthy donor
<i>NHL</i>	Non-hodgkin's lymphoma
<i>NK</i>	Natural killer
<i>NLE</i>	Neonatal lupus erythematosus
<i>NPV</i>	Negative predictive value
<i>NSAIDS</i>	Non steroidal anti-inflammatory drugs
<i>NuHi</i>	Nucleo-histones
<i>P VALUE</i>	Predictive value
<i>PAH</i>	Pulmonary arterial hypertension
<i>PARP</i>	Poly ADP ribose polymerase
<i>PBMCs</i>	Peripheral blood mononuclear cells
<i>PCNA</i>	Proliferating cell nuclear antigen
<i>PDCD</i>	Programmed cell death
<i>PG</i>	Picogram
<i>PLT</i>	Platelet
<i>PPV</i>	Positive predictive value
<i>PR/CR</i>	Protein /creatinine

<i>PS</i>	Phosphatidylserine
<i>PTPN22</i>	Protein tyrosine phosphatase non receptor type
<i>PXK</i>	Px domain containing serine/threonine kinase.
<i>RA</i>	Rheumatoid arthritis
<i>RBC</i>	Red blood cell
<i>RF</i>	Rheumatoid factor
<i>RNA</i>	Ribonucleic acid
<i>RNP</i>	Ribonucleoprotein
<i>Ro(SSA)</i>	Ro ssa antigen
<i>ROC</i>	Receiver operating characteristic
<i>RPGN</i>	Rapidly progressive glomerulonephritis
<i>RTEC</i>	Reticuloendothelial cells
<i>RT-PCR</i>	Reverse transcriptase polymerase chain reaction
<i>S.CREAT.</i>	Serum creatinine
<i>SCLE</i>	Subacute cutaneous lupus erythematosus
<i>SD</i>	Standard deviation
<i>SLE</i>	Systemic lupus erythematosus
<i>SLEDAI</i>	Systemic lupus erythematosus disease activity index
<i>SLO</i>	Secondary lymphoid organs
<i>SN</i>	Sensitivity
<i>SP</i>	Specificity
<i>SSc</i>	Systemic sclerosis
<i>SST</i>	Serum separator tube
<i>STAT4</i>	Signal transducer and activator of transcription 4
<i>T reg</i>	T regulatory cells

<i>TBM</i>	Tingible body macrophage
<i>TCR</i>	T cell receptor
<i>TFH</i>	Follicular t helper cell
<i>TGF</i>	Transforming growth factor
<i>Th</i>	T helper cell
<i>TLC</i>	Total leucocytic count
<i>TN</i>	True negative
<i>TNF</i>	Tumor necrosis factor
<i>TP</i>	True positive
<i>U1sn-RNP</i>	U1 small nuclear ribonucleoprotein
<i>UV</i>	Ultra violet
<i>VCAM-1</i>	Vascular cell adhesion molecule-1
<i>WBC</i>	White blood cell
<i>WG</i>	Wegener's granulomatosis

List of Figures

Figure No.	Comment	Page No.
1	Interaction between a T cell and an antigen-presenting cell	21
2	Summary of abnormal cytokine profiles in skin, kidney and neurological systems	24
3	Defects in the clearance of apoptotic cells.	27
4	Induction of Surface Blebs during apoptosis	28
5	Pathogenesis of SLE	32
6	Pathogenesis of lupus: role of T-B cell diversification	33
7	An algorithm for the diagnosis of SLE.	50
8	Three dimensional structure of chemokine	60
9	structure of chemokines classes	61
10	Schematic structure of fractalkine	62
11	Membrane-bound fractalkine/CX3C	63
12	Schematic model of classical and fractalkine-mediated pathways in the adhesion cascade.	66
13	Migration of mature monocytes and killer lymphocytes by CX3CR1 fractalkine axis	68
14	Biological functions of fractalkine	69
15	Fractalkine- mediated pathophysiological conditions	72
16	CX3CR1 in primary tumors of the nervous system and metastasis. Different tumors expressing CX3CR1 are represented, together with the organs or tissues which are the site of secondary localization	85

17	Principle of sandwich enzyme linked immunosorbant assay	87
18	(I and J), (I) Hematoxylin and eosin staining of kidney sections from 30-week-old AdTACI-Ig- or AdBAFF-R-Ig-treated mice showed markedly reduced glomerular damage (J) as compared with 30-week-old untreated controls.	89
19	Schematic drawing of the PCR cycle	92
20	ROC curve analysis showing the diagnostic performance of CX3CL1 for discriminating SLE patients from controls	126
21	ROC curve analysis showing the diagnostic performance of CX3CL1 for discriminating Active patients from Inactive SLE patients	127
22	ROC curve analysis showing the diagnostic performance of CX3CL1 for discriminating moderate from mild active SLE patients	128
23	ROC curve analysis showing the diagnostic performance of CX3CL1 for discriminating severe patients from other active patients	129
24	ROC curve analysis showing the diagnostic performance of CX3CL1 for discriminating V. severe patients from other active patients	130
25	ROC curve analysis showing the diagnostic performance of CX3CL1 for discriminating V. severe and severe patients from mild and moderate patients	131

List of Tables

Table No.	Comment	Page No.
1	The currently known genes and gene regions associated with SLE	11
2	Important cytokines in SLE: the major secreting cells and possible clinical applications	25
3	The 1997 update of the 1982 ACR revised criteria (ACR97) for classification of SLE	45
4	Different autoantibodies and their clinical correlations in SLE	49
5	Imaging studies used in cases of SLE	53
6	SLE disease activity index	57
7	Profiles of CX3CR1- expressing cells	71
8	Descriptive statistics of various studied parameters in all SLE patients' group, inactive SLE patients' group, active SLE patients' group and control group	120
9	Comparative statistics of various studied parameters between different studied groups using Wilcoxon's Rank sum test for non parametric data and student's t test for parametric data	121
10	Descriptive statistics of different studied parameters in different active SLE subgroups (mild, moderate, severe and very severe SLE activity subgroups)	122

11	Comparative statistics of various studied parameters between different active SLE patients' subgroups using Wilcoxon's Rank sum test for non parametric data and student's t test for parametric data	123
12	Correlations analysis between serum CX3CL1 and different studied laboratory parameters among control group, all SLE patients, inactive SLE group and active SLE group using Ranked Spermman's Correlation test	124
13	Diagnostic validity tests of CX3CL1 for discrimination between different studied groups	125